GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (FRA:GBM) » Definitions » Cyclically Adjusted Price-to-FCF

Inovio Pharmaceuticals (FRA:GBM) Cyclically Adjusted Price-to-FCF : (As of Jun. 14, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Inovio Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inovio Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Inovio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Inovio Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Inovio Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Inovio Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.137/131.7762*131.7762
=-1.137

Current CPI (Mar. 2024) = 131.7762.

Inovio Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.293 100.560 -1.694
201409 -1.285 100.428 -1.686
201412 -1.319 99.070 -1.754
201503 -2.293 99.621 -3.033
201506 -1.524 100.684 -1.995
201509 2.117 100.392 2.779
201512 -1.156 99.792 -1.527
201603 -2.450 100.470 -3.213
201606 -2.340 101.688 -3.032
201609 -2.770 101.861 -3.584
201612 -2.299 101.863 -2.974
201703 -2.418 102.862 -3.098
201706 -3.082 103.349 -3.930
201709 -2.416 104.136 -3.057
201712 -1.660 104.011 -2.103
201803 -1.477 105.290 -1.849
201806 -2.194 106.317 -2.719
201809 -2.759 106.507 -3.414
201812 -1.934 105.998 -2.404
201903 -3.607 107.251 -4.432
201906 -2.599 108.070 -3.169
201909 -2.954 108.329 -3.593
201912 -1.492 108.420 -1.813
202003 -2.230 108.902 -2.698
202006 -1.859 108.767 -2.252
202009 -4.355 109.815 -5.226
202012 -2.949 109.897 -3.536
202103 -2.643 111.754 -3.117
202106 -3.739 114.631 -4.298
202109 -2.263 115.734 -2.577
202112 -1.922 117.630 -2.153
202203 -3.080 121.301 -3.346
202206 -2.438 125.017 -2.570
202209 -3.279 125.227 -3.451
202212 -1.643 125.222 -1.729
202303 -1.603 127.348 -1.659
202306 -1.355 128.729 -1.387
202309 -1.219 129.860 -1.237
202312 -1.060 129.419 -1.079
202403 -1.137 131.776 -1.137

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inovio Pharmaceuticals  (FRA:GBM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Inovio Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (FRA:GBM) Business Description

Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Inovio Pharmaceuticals (FRA:GBM) Headlines

No Headlines